A Study of the Effects of Exendin-9,39 on Glucose Metabolism, Glucagon and Insulin Secretion, and on Insulin Action

Overview

About this study

The purpose of the study is to examine the effect of different dosages of Exendin on glucose metabolism, glucagon and insulin secretion, and on insulin action.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

This study has been completed

Inclusion Criteria

  • Healthy
  • Not on any medication other than thyroid hormone replacement or OCP
  • No history of diabetes
  • No prior upper GI surgery

Exclusion Criteria

  • Age < 20 years or > 45
  • Fasting glucose > 100mg/dL
  • Not taking medications other than stable thyroid hormone replacement or oral contraceptives 

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20312914

Mayo Clinic Footer